RxDoctor Payments Data

Jacqueline Kreft, PA

Physician Assistant · Lansing, MINPI 1619495082

Payments from drug & device makers

$5,647in general payments, 2019–2025

Across 186 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$736
  • Pfizer$475
  • E.r. Squibb & Sons, L.L.C.$442
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$406
  • Medtronic$396
  • Abbott$393
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$5,48897%
  • Education$1593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,647 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$20,685
Medicare patients
204
Services billed
283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban440$575,951
XareltoRivaroxaban114$137,033
EntrestoSacubitril/Valsartan84$106,718
Repatha SureclickEvolocumab136$83,743
JardianceEmpagliflozin34$45,586
MultaqDronedarone Hcl25$44,340
FarxigaDapagliflozin Propanediol32$29,894
Praluent PenAlirocumab24$17,331
Dofetilide46$8,263
Rosuvastatin Calcium271$6,580
Metoprolol Succinate332$6,357
Ranolazine ErRanolazine54$5,726
Amiodarone Hcl79$4,714
Atorvastatin Calcium258$4,530
Carvedilol296$4,521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$475$575,951440 claims
Johnson & JohnsonXarelto$173$137,033114 claims
NovartisEntresto$318$106,71884 claims
Boehringer IngelheimJardiance$285$45,58634 claims
Sanofi-aventis U.S. LLCMultaq$21$44,34025 claims
AstraZenecaFarxiga$82$29,89432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →